The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Novel therapies for patients with MCL after failed response to BTK inhibitors
In this video, Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, highlights some of the most promising therapies for patients with mantle cell lymphoma (MCL) following failed response to Bruton’s tyrosine kinase (BTK) inhibitor therapy. Dr Phillips draws focus on the major impact of chimeric antigen receptor T-cell (CAR-T) therapy, as well as the safety and efficacy of bispecific antibodies such as pirtobrutinib, and how these therapeutic options can improve future outcomes for patients with MCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
